CTI Website
  • Company
    • About Us
    • Leadership
    • Partnering
    • Contact
  • Medicines
    • VONJO® (pacritinib)
    • CTI Access
    • Medicine Support
    • Compliance & Transparency
  • Development
    • Development Overview
    • Myelofibrosis Program
    • Clinical Trials
    • Expanded Access
    • Publications & Posters
  • Careers
    • Our Culture
    • Job Openings
    • Diversity & Inclusion
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • Annual Report
      • Quarterly Reports
      • Stockholder Meeting
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Whistleblower Hotline
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • Contact IR
  • Contact
  • Patient Resources
  • Contact
  • Patient Resources
Select Page

Pacritinib

by [email protected] | Sep 28, 2021

Footer logo

Company

  • About Us
  • Leadership
  • Partnering
  • Contact

Medicines

  • VONJO® (pacritinib)
  • CTI Access
  • Medicine Support
  • Compliance & Transparency

Development

  • Development Overview
  • Myelofibrosis Program
  • Clinical Trials
  • Expanded Access
  • Publications & Posters

Careers

  • Our Culture
  • Job Openings
  • Diversity & Inclusion

Investors & Media

  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
  • Financial Information
  • Corporate Governance
  • Investor Resources
Footer logo
© 2022 CTI BIOPHARMA CORP. CTI and VONJO are trademarks of CTI BioPharma Corp.
  • Privacy Notice
  • Terms of Use
  • Cookie Notice

This site uses cookies to improve the browsing experience. Please visit our Privacy Policy page for more information.

Accept